10-Q: Aligos Therapeutics Q3 Loss Narrows, HBV Drug Advances

Aligos Therapeutics reports a reduced net loss for the nine months ended September 30, 2025, driven by a significant fair value change in warrants, while advancing its lead HBV drug into Phase 2 and exploring funding options amid a going concern warning.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $4.3 million from $49.1 million in the prior year, primarily due to a $59.0 million gain from the change in fair value of 2023 common warrants.
• For the three months ended September 30, 2025, net loss increased to $31.5 million from $19.3 million in the prior year, mainly due to a $4.2 million decrease in the fair value of 2023 common warrants and increased R&D expenses.
• Cash, cash equivalents, and short-term investments totaled $99.1 million as of September 30, 2025, up from $56.9 million at December 31, 2024, following a $105.0 million PIPE offering in February 2025.
• The company expects its current cash to fund operations into the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern beyond that period without additional funding.
• Research and development expenses increased by $7.2 million for the three months ended September 30, 2025, to $23.9 million, primarily due to increased clinical study costs for the pevifoscorvir sodium Phase 2a trial, including a $9.0 million milestone payment to Emory University.
• The Phase 2 B-SUPREME study for pevifoscorvir sodium (chronic HBV) has obtained worldwide regulatory approvals, is activating global sites, and enrolled its first subject in August 2025, with interim data expected in H1 and H2 2026, and topline data in 2027.
• ALG055009 (obesity and MASH) Phase 2a HERALD study showed statistically significant reductions in liver fat, with up to 70% of subjects achieving a 30% relative reduction. The company is evaluating options to fund its continued development, including potential out-licensing.
• ALG097558 (pan-coronavirus) has completed a Phase 1 study and advanced into a Phase 2 study in high-risk COVID-19 patients, with future development expected to be funded by external sources, including NIH awards totaling approximately $15.3 million.

Sentiment

Score: 4

Explanation: While the company has positive clinical data for its lead candidates and successfully raised capital, the increased quarterly net loss, declining revenue, and explicit 'going concern' warning indicate significant financial challenges and uncertainty. The positive clinical progress is offset by the financial instability and the long, costly path to commercialization.

Positives

• Net loss for the nine months ended September 30, 2025, significantly decreased to $4.3 million from $49.1 million in the prior year, largely due to a $59.0 million gain from the change in fair value of 2023 common warrants.
• Cash, cash equivalents, and short-term investments increased to $99.1 million as of September 30, 2025, from $56.9 million at December 31, 2024, bolstered by a $105.0 million PIPE offering.
• Pevifoscorvir sodium (chronic HBV) Phase 1 data showed potentially best-in-class potent and durable antiviral activity, with sustained HBV DNA suppression in 60% of HBeAg+ subjects at Week 48 and 100% at Week 96, and in all HBeAgsubjects by Week 24, maintained for up to 96 weeks.
• Pevifoscorvir sodium also demonstrated concurrent multi-log10 reductions in HBV antigens (HBsAg, HBeAg, and HBcrAg) in HBeAg+ subjects and HBcrAg decline in HBeAgsubjects, suggesting potential inhibition of cccDNA establishment.
• The Phase 2 B-SUPREME study for pevifoscorvir sodium has obtained worldwide regulatory approvals, is activating global sites, and dosed its first subject in August 2025.
• ALG055009 (obesity and MASH) Phase 2a HERALD study met its primary endpoint with statistically significant reductions in liver fat (up to 46.2% placebo-adjusted median relative reduction) at Week 12, and demonstrated a favorable tolerability profile.
• Preclinical data for ALG-055009 showed profound synergistic effects when combined with semaglutide or tirzepatide for weight loss in a diet-induced obese mouse model.
• ALG097558 (pan-coronavirus) has completed a Phase 1 study and advanced into a Phase 2 study, showing at least 3-fold more potency than other approved CoV PIs in cell-based assays and suggesting ritonavir co-dosing may not be required.
• The ALG097558 program is partially funded by NIH awards and contracts, with approximately $15.3 million expected.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $31.5 million from $19.3 million in the prior year, primarily due to a $4.2 million decrease in the fair value of 2023 common warrants and increased R&D expenses.
• The company has incurred significant losses since inception, with an accumulated deficit of $622.3 million as of September 30, 2025.
• Revenue from collaborations was $0 for both the three and nine months ended September 30, 2025, down from $19 thousand and $311 thousand respectively in 2024, due to the termination of the Merck collaboration agreement.
• Revenue from customers decreased by $0.5 million (41%) for the three months and $1.0 million (33%) for the nine months ended September 30, 2025, compared to the same periods in 2024, due to the near completion of a higher-value Amoytop agreement and the start of a lower-value extension.
• The company expects its current cash, cash equivalents, and short-term investments to fund operations only into the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern.
• Research and development expenses increased by $7.2 million (43%) for the three months ended September 30, 2025, compared to the same period in 2024, driven by increased clinical study costs for pevifoscorvir sodium Phase 2a trial.
• The company has no products approved for commercial sale and has never generated revenue from product sales, making future profitability uncertain.
• Past discontinuations of drug candidates (ALG-010133 and ALG-020572) highlight the high failure rate in drug development.
• Further clinical evaluation of ALG-125755 (siRNA drug candidate) is not prioritized with current funding and requires additional external funding.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale, having incurred significant losses since inception and expecting to incur losses for at least the next several years, making future viability difficult to assess.
• Substantial additional financing will be required to achieve goals, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or termination of product development or commercialization efforts, and impacting the ability to continue as a going concern.
• The business is dependent on the successful development of current and future drug candidates, which are in early or mid-stages. Failure to advance through clinical trials, obtain marketing approval, or commercialize, or significant delays, would materially harm the business.
• Current or future drug candidates may cause undesirable side effects or have other properties that could delay or halt clinical development, prevent marketing approval, limit commercial potential, or result in significant negative consequences.
• The company depends on collaborations with third parties for the development of certain potential drug candidates, and may depend on additional collaborations in the future. Unsuccessful collaborations could prevent capitalization on market potential.
• Intent to develop drug candidates in combination with other therapies exposes the company to additional risks, including issues with the co-administered therapies.
• The company faces significant competition, and if competitors develop and market products that are more effective, safer or less expensive than the drug candidates developed, commercial opportunities will be negatively impacted.
• If the company and its collaborators are unable to obtain, maintain, protect and enforce sufficient patent and other intellectual property protection for drug candidates and technology, competitors could develop and commercialize similar products, hindering effective competition or commercialization.
• Third parties may initiate legal proceedings alleging infringement, misappropriation or violation of their intellectual property rights, leading to uncertain outcomes and negative business impact.
• Failure to comply with obligations in licensing and collaboration agreements, or termination of these agreements, could harm competitive position, business, financial condition, results of operations, and prospects.
• The company is highly dependent on key personnel; failure to attract, motivate, and retain highly qualified personnel could impede successful implementation of business strategy.
• Quarterly and annual operating results may fluctuate significantly due to various factors, making future results difficult to predict and potentially causing results to fall below expectations.
• The business could be materially adversely affected by the effects of health pandemics or epidemics, particularly in regions with significant manufacturing facilities, clinical trial sites, or other business operations.
• Nonclinical development is uncertain. Nonclinical programs may experience delays or never advance to clinical trials, adversely affecting regulatory approvals or timely commercialization.
• The regulatory approval processes are lengthy, expensive, complex, and inherently unpredictable, potentially preventing or delaying approval.
• Even if approved, drug candidates may fail to achieve sufficient market acceptance by physicians, patients, third-party payors, and others.
• Adverse events in therapeutic areas of focus could damage public perception of drug candidates and negatively affect the business.
• Patent terms may be insufficient to establish a competitive position for an adequate amount of time, leading to earlier generic competition.
• Risks associated with international trade policies (e.g., tariffs) or international operations, including seeking foreign approvals, could harm the business.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, shutdowns) could hinder their ability to review and approve products.
• Market opportunities for drug candidates may be smaller than believed, or approvals based on narrower patient definitions, impacting business.
• Reliance on third parties for manufacturing nonclinical, clinical, and commercial drug supplies increases risks of insufficient quantities or unacceptable costs, delaying or impairing development/commercialization.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws, potentially leading to criminal sanctions, civil penalties, etc.
• Business and operations may suffer if IT systems, or those of CROs/contractors, fail or suffer security breaches, leading to data loss, operational disruption, or legal/financial harm.
• Risk of employees, contractors, and collaborators engaging in misconduct or improper activities, including non-compliance with regulatory standards and insider trading.
• The company currently has no sales organization; inability to establish sales capabilities could hinder effective marketing and sales.
• The need to grow the organization may lead to difficulties in managing growth and impose significant responsibilities on management.
• Failure to comply with environmental, health, and safety laws could result in fines, penalties, or costs.
• The company may be adversely affected by earthquakes, wildfires, or other natural disasters, especially with headquarters in the San Francisco Bay Area, with limited disaster recovery plans and no earthquake insurance.
• The price of common stock may be volatile and fluctuate substantially, leading to potential losses for investors.
• The dual class structure of common stock may limit ability to influence corporate matters and visibility of certain transactions.
• Sales of substantial shares in the public market could cause stock price to fall; future financings may cause immediate dilution.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• If securities analysts do not publish research or publish negative evaluations, stock price could decline.
• Failure to implement and maintain proper and effective internal control over financial reporting could impair ability to produce accurate financial statements.
• Provisions in charter documents and Delaware law could discourage takeovers and lead to management entrenchment.
• Claims for indemnification by directors and officers may reduce available funds.
• An exclusive forum provision in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Unfavorable global economic conditions could adversely affect business, financial condition, stock price, and results of operations.
• Insurance policies are expensive and protect only from some business risks, leaving exposure to significant uninsured liabilities.
• The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, violations of which can have serious negative consequences.
• Changes in patent law could diminish the value of patents, impairing ability to protect drug candidates.
• Inability to protect confidentiality of trade secrets could harm business and competitive position.
• If trademarks and trade names are not adequately protected, name recognition and business may be adversely affected.
• Future strategic transactions could affect liquidity, dilute stockholders, increase expenses, and present management challenges.
• Litigation or administrative proceedings could have a material adverse effect on business, financial condition, and results of operations.
• The company incurs significantly increased costs as a public company, with management devoting substantial time to compliance.
• Fluctuations in tax obligations and effective tax rate could materially and adversely affect results of operations.
• If estimates or judgments relating to critical accounting policies are based on assumptions that change or prove incorrect, operating results could fall below expectations.

Future Outlook

The company expects to incur significant expenses and increasing operating losses over at least the next several years and does not anticipate generating revenue from product sales for several years, if ever. Research and development expenses, particularly for pevifoscorvir sodium and MASH programs, are projected to increase. General and administrative expenses are also expected to rise. Current cash, cash equivalents, and short-term investments are anticipated to fund operations only into the third quarter of 2026, necessitating substantial additional capital raises beyond that period. Interim data for the pevifoscorvir sodium Phase 2 B-SUPREME study is projected in H1 and H2 2026, with topline data in 2027. The company is evaluating out-licensing options for ALG-055009 and expects external funding for ALG097558's future development.

Management Comments

• "We expect to continue to incur significant expenses and increasing operating losses over at least the next several years."
• "We do not expect significant future revenue from collaborations at this time."
• "We do not expect significant future revenue from customers at this time."
• "We expect research and development expenses will increase in future periods as we continue to focus on advancing clinical trials for pevifoscorvir sodium and MASH."
• "We expect general and administrative expenses will increase in future periods due to increased activity in our research and development group, which will require more resources and additional activities in our general and administration group."
• "Our current operating plan and projected cash outflows for the upcoming periods raise doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report."
• "We plan to raise additional capital to fund continued operations beyond the third quarter of 2026."
• "We are taking steps to identify access to future capital and expect to be able to access capital in the future."
• "However, there can be no assurance that any additional funding will be available to us on acceptable terms, if at all."
• "We believe ALG-055009 warrants further development as a potential treatment for both obesity and MASH."

Industry Context

The biopharmaceutical industry is highly competitive, characterized by rapid technological change and significant investment in R&D. Aligos Therapeutics operates in the clinical-stage segment, focusing on liver and viral diseases, including chronic HBV, MASH, obesity, and coronaviruses. The market for chronic HBV treatments is dominated by existing oral antiviral agents that offer viral suppression but rarely functional cure, creating an unmet need that Aligos aims to address with its CAMEs and ASOs. The MASH and obesity markets are also highly competitive, with new approvals like resmetirom (Madrigal Pharmaceuticals) and established GLP-1 receptor agonists for weight loss. Aligos's ALG055009 aims for enhanced potency and selectivity compared to existing THR-agonists. For coronaviruses, the market is rapidly evolving with approved oral antivirals (Paxlovid by Pfizer, molnupiravir by Merck) and numerous vaccine developments, posing a challenge for new entrants. The industry also faces increasing scrutiny over drug pricing and data privacy regulations (e.g., IRA, GDPR, DSP), which can impact commercialization and operational costs. Mergers and acquisitions among larger pharmaceutical companies further intensify competition for resources and talent.

Comparison to Industry Standards

• Pevifoscorvir sodium (HBV CAME) pre-clinical data suggests superior DMPK properties with enhanced absorption and high liver uptake, and a ~2-300-fold improvement in in vitro potency compared to other known CAMs.
• Phase 1 data for pevifoscorvir sodium suggests it may be superior to current standard of care nucleos(t)ide analogs (NAs) like tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in achieving HBV DNA levels <LLOQ after 48 weeks.
• Pevifoscorvir sodium demonstrated concurrent multi-log10 reductions in HBV antigens, which competitor CAMEs have rarely or inconsistently shown.
• ALG055009 (THR-agonist for MASH/Obesity) is designed to exhibit significantly greater potency (approximately 50-fold higher compared to resmetirom in head-to-head in vitro studies) and enhanced selectivity.
• Preclinical data for ALG-055009 showed profound synergistic effects when combined with incretin RAs like semaglutide or tirzepatide, suggesting potential for enhanced weight loss beyond monotherapy.
• ALG097558 (Pan-coronavirus PI) preclinical studies showed it to be at least 3-fold more potent than nirmatrelvir and other PIs in clinical development against SARS-CoV-2 variants.
• Phase 1 data for ALG097558 suggests ritonavir boosting may not be required, unlike some approved PIs (e.g., Paxlovid, which is co-administered with ritonavir).

Corporate Governance

Legal Proceedings

• The company is not currently involved in any legal proceedings that are believed to be individually or in the aggregate, material to its business, results of operations or financial condition.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises (equity offerings, convertible debt). Stock price volatility is a risk. The dual-class stock structure may limit influence for common stockholders. Existing stockholders (executive officers, directors, affiliates) have significant influence (65% of outstanding common stock, 33% assuming warrant exercise).
• Employees face potential for reductions in staff if additional funding is not secured, impacting job security. Competition for skilled personnel is intense.
• Future customers (patients) may benefit from new therapeutic options for chronic HBV, MASH, obesity, and coronaviruses if drug candidates are successfully developed and commercialized. Delays or termination of development programs would negatively impact patient access to these potential treatments.
• Suppliers and creditors may face increased risk due to the 'going concern' warning, potentially affecting terms of engagement.

Next Steps

• Continue advancing clinical trials for pevifoscorvir sodium and MASH.
• Present 96-week safety, PK, antiviral activity, and post-treatment data for pevifoscorvir sodium Phase 1 at upcoming scientific conferences.
• Activate global sites and enroll subjects for the Phase 2 B-SUPREME study for pevifoscorvir sodium.
• Present interim data for the pevifoscorvir sodium Phase 2 B-SUPREME study in H1 and H2 2026.
• Anticipate topline data for the pevifoscorvir sodium Phase 2 B-SUPREME study in 2027.
• Explore additional ways to potentially treat chronic HBV infection, including antisense oligonucleotide (ASO) platform and a novel strategy for hepatitis delta virus (HDV) coinfection.
• Select a clinical development candidate for the HDV program.
• Evaluate a variety of options to fund continued development of ALG-055009, including potential out-licensing.
• Present preclinical data combining ALG-055009 with incretin RAs at a future scientific conference.
• Seek additional external funding (e.g., from governmental agencies) and/or collaborations (e.g., platform trials) to support future studies for ALG097558.
• Raise substantial additional capital to fund operations beyond the third quarter of 2026.

Key Dates

Recommendation

Aligos Therapeutics presents a high-risk, high-reward profile. The company has promising clinical data for its lead candidates (pevifoscorvir sodium, ALG055009, ALG097558) which show potential best-in-class properties and address significant unmet medical needs. The recent $105.0 million PIPE offering provides a temporary liquidity boost. However, the explicit 'going concern' warning, indicating that current cash will only last into Q3 2026, highlights severe financial instability and the urgent need for substantial additional capital. The increased quarterly net loss and declining collaboration/customer revenue further underscore the financial challenges. Given the early-to-mid-stage nature of its pipeline, the long and costly path to commercialization, and the inherent uncertainties of drug development, the stock is speculative. A 'hold' recommendation acknowledges the clinical potential while emphasizing the significant financial risks and the need for investors to monitor future financing efforts and clinical milestones closely before making further investment decisions. The stock is not a 'buy' due to the going concern risk and not a 'sell' due to the promising clinical data and recent capital raise.

Keywords

Biotechnology, Clinical-stage, HBV, MASH, Obesity, Coronavirus, Drug development, Clinical trials, 10-Q, Financial results, Going concern, PIPE offering, Pevifoscorvir sodium, ALG055009, ALG097558, Capsid Assembly Modulator, THR-agonist, Protease Inhibitor, Intellectual property, Regulatory approval, Biopharmaceutical, Liver diseases, Viral infections